Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab (SHP647) Long-Term Safety in Ulcerative Colitis (TURANDOT II)
NCT01771809Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2013
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 2 trial of ontamalimab in ulcerative colitis (UC), sponsored by Takeda. Started Mar 2013; status: completed.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01771809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01771809.